Food Animal Health and Management Program, College of Veterinary Medicine, University of Georgia, Athens, GA.
Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA.
J Anim Sci. 2018 Apr 14;96(4):1259-1267. doi: 10.1093/jas/sky054.
Bovine respiratory disease (BRD) is the most common cause of morbidity and mortality in North American beef cattle. Mannheimia haemolytica is the bacterial pathogen most often isolated from cattle with BRD, and the prevalence of antimicrobial resistance (AMR) in this organism has increased in recent years. Antimicrobials are commonly used to prevent BRD in cattle at high risk of developing BRD; however, recent work would suggest that this practice might be one factor contributing to the increased prevalence of AMR in M. haemolytica. We hypothesized that the administration of the short-acting fluoroquinolone, enrofloxacin, would be just as effective as the long-acting triamilide, tulathromycin, in preventing BRD but would be less likely to select for AMR M. haemolytica in stocker calves at high risk of developing BRD. Three hundred forty-one stocker calves were enrolled in the study with 172 calves in 4 pens being randomly assigned to treatment with enrofloxacin and 169 calves in 4 pens randomly assigned to treatment with tulathromycin. Calves within each treatment group were allocated to one of 4 replicate pens based on the week of enrollment. Of calves receiving enrofloxacin, 33.7% required treatment for BRD at least once within 45 d after arrival, compared with 18.3% of calves receiving tulathromycin (P = 0.040). The percentages of calves that required more than one treatment for BRD within 45 d after arrival did not differ statistically for those receiving enrofloxacin compared with those receiving tulathromycin (10.5% and 4.7%, respectively; P = 0.107) Likewise, the percentages of calves that died during the 45-d follow-up period did not differ for those receiving enrofloxacin compared with those receiving tulathromycin (12.2% and 10.1%, respectively; P = 0.592). Mannheimia haemolytica was cultured from 11% of calves sampled at arrival and from 50% of calves sampled at revaccination 14 to 17 d later. There was a significanst effect of sampling time on the proportion of calves carrying multidrug-resistant (MDR) isolates, with calves having a higher prevalence of MDR isolates at revaccination than arrival (100% vs. 13%; P < 0.001). Future research evaluating the impact of MDR on response to antimicrobial therapy is necessary.
牛呼吸道疾病(BRD)是北美肉牛发病率和死亡率最高的疾病。曼海姆菌是从患有 BRD 的牛中最常分离到的细菌病原体,近年来,该病原体对抗微生物药物的耐药性(AMR)的流行率有所增加。在有发生 BRD 高风险的牛中,通常使用抗生素来预防 BRD;然而,最近的研究表明,这种做法可能是导致曼海姆菌 AMR 流行率增加的一个因素。我们假设,使用短效氟喹诺酮类药物恩诺沙星,与长效三氨酰胺类药物替米考星一样,能有效预防 BRD,但在有发生 BRD 高风险的育肥牛中,它不太可能选择出 AMR 曼海姆菌。本研究共纳入 341 头育肥牛,其中 172 头牛被随机分配到恩诺沙星组,169 头牛被随机分配到替米考星组,每组 4 个围栏。每个治疗组的牛根据入组周被分配到 4 个重复围栏中的 1 个。在接受恩诺沙星治疗的牛中,33.7%的牛在到达后 45 天内至少需要治疗一次 BRD,而接受替米考星治疗的牛中这一比例为 18.3%(P=0.040)。在到达后 45 天内,需要不止一次治疗 BRD 的牛的比例,接受恩诺沙星治疗的牛与接受替米考星治疗的牛之间没有统计学差异(分别为 10.5%和 4.7%;P=0.107)。同样,在 45 天的随访期间,接受恩诺沙星治疗的牛与接受替米考星治疗的牛的死亡率也没有差异(分别为 12.2%和 10.1%;P=0.592)。在到达时,从 11%的采样牛中分离到曼海姆菌,在到达后 14 至 17 天再接种疫苗时,从 50%的采样牛中分离到曼海姆菌。采样时间对携带多药耐药(MDR)分离株的牛的比例有显著影响,与到达时相比,再接种疫苗时牛携带 MDR 分离株的比例更高(100%比 13%;P<0.001)。有必要开展评估 MDR 对抗菌治疗反应影响的未来研究。